Sarepta: A-OK from the FDA?

This drug maker’s share price is rising after an analyst says he sees “a compelling argument” for accelerated FDA approval of a next-generation therapy for Duchenne muscular dystrophy
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>